Novo Nordisk has confirmed it submitted a takeover bid for biotech company Metsera. The Danish pharmaceutical giant aims to surpass competitor Pfizer in acquiring the biotechnology firm.
Novo Nordisk disclosed the offer in a stock exchange announcement on Thursday. The company proposed $56.50 per share for Metsera. Additional payments could reach $21.25 per share if certain performance targets are met.
The bid now goes to Metsera's board of directors for review. They are currently examining the proposal.
Pfizer had previously agreed to acquire Metsera in September. Their deal offered $47.50 per share plus milestone payments up to $22.50 per share.
Metsera shareholders must approve any acquisition at an extraordinary general meeting scheduled for November 13. The competing bids create a clear choice for investors between two major pharmaceutical players.
This bidding war highlights the intense competition for promising biotech assets. Novo Nordisk's aggressive move signals its determination to expand beyond its successful weight-loss treatments.
Why would a Danish company challenge an American pharmaceutical giant? The answer lies in the strategic value of biotech innovations. Both companies see Metsera's research as crucial for future growth.
The higher upfront payment from Novo Nordisk might appeal to shareholders seeking immediate returns. Yet Pfizer's established global presence could offer better long-term development capabilities.